Skip to content
DataLookout
Menu

NCT01089101

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 194 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria shortened, about 425 words
  2. Notable Eligibility criteria expanded, about 687 words
    • Secondary endpoints: 4 to 7
    • Study description expanded, about 1 word
  3. New version filed on ClinicalTrials.gov
  4. Minor Enrollment target: estimated 220 to confirmed 217
    • Primary completion date changed from estimate of Jul 31, 2026 to Jan 17, 2026
    • Study completion date: Jul 31, 2026 to Mar 18, 2027
    v174
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of patients who experienced dose limiting toxicities (DLTs) (phase I)
Timeframe: 28 days
Maximum tolerated dose and recommended phase 2 dose of selumetinib determined by dose-limiting toxicities (phase I)
Timeframe: 28 days
Proportion of subjects with objective response (complete response or partial response) sustained for 8 weeks (phase II)
Timeframe: 104 weeks
Proportion of subjects with objective response (complete response or partial response) sustained for 8 weeks (re-treatment study)
Timeframe: Up to 380 weeks
Proportion of subjects with disease stabilization (re-treatment study)
Timeframe: At 1 year

Secondary (7)

Pharmacokinetic parameters for selumetinib and N-desmethyl selumetinib (phase I)
Stratum-specific percent probability progression-free survival (PFS) (phase II)
Number of patients with presence or absence of BRAF V600E mutations or BRAF KIAA1549 fusion (phase II)
Proportion of subjects with objective response (complete response or partial response) sustained for 8 weeks according to BRAF aberration type (phase II)
Stratum-specific percent probability of progression-free survival (PFS) according to BRAF aberration type (phase II)
Show 2 moreShow less
Proportion of patients with MAPK aberrations (phase II)
Percent probability progression-free survival (retreatment study)

Arms and interventions

Treatment (selumetinib)Experimental

Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities. Patients undergo blood sample collection on study.

Procedures: Biospecimen Collection

Drugs: Selumetinib

Sites

17 sites in 1 country